^
Association details:
Biomarker:IL6 elevation
Cancer:Cervical Cancer
Drug:Yervoy (ipilimumab) (CTLA4 inhibitor)
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Title:

Immune activation in patients with locally advanced cervical cancer treated with ipilimumab following definitive chemoradiation (GOG-9929)

Published date:
08/18/2020
Excerpt:
A Phase I clinical trial (GOG-9929) examined the safety and efficacy of adjuvant immune modulation therapy with the checkpoint inhibitor ipilimumab (anti-CTLA4) following chemoradiation therapy (CRT) for newly diagnosed node-positive human papillomavirus (HPV)-related cervical cancer. Elevation in levels of tumor-promoting circulating cytokines (TNFα, IL-6, IL-8) post-CRT were significantly associated with worse progression-free survival.
DOI:
10.1158/1078-0432.CCR-20-0776